ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August 14, 2017 we issued a press release disclosing the financial results for our second quarter ended June 30, 2017. A copy of our press release is being furnished as Exhibit 99.1 hereto.
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On August 8, 2017, the Compensation Committee of our Board of Directors (“Board”) recommended the grant of a one-time $20,000 cash bonus (the “Bonus”) to Peter Clemens, our Senior Vice President and Chief Financial Officer, which Bonus was approved by our Board on August 9, 2017. The Bonus is payable as part of our next payroll cycle and subject to applicable withholding.
| Item 9.01 | Financial Statements and Exhibits |
| Exhibit Number | Description |
| 99.1 | Press Release dated August 14, 2017 announcing financial results for the second quarter ended June 30, 2017. |
ACURA PHARMACEUTICALS, INC ExhibitEX-99.1 2 v473213_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Acura Pharmaceuticals Announces Second Quarter 2017 Financial Results Palatine,…To view the full exhibit click here
About ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR)
Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.
